Meeting
2013 ASCO Annual Meeting
Effect of age on impact of adjuvant chemotherapy for resected non-small cell lung cancer.
Authors
Apar Kishor Ganti
VA Nebraska-Western Iowa Health Care System, Omaha, NE
Apar Kishor Ganti , Christina D. Williams , Ajeet Gajra , Michael J. Kelley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7539)
DOI
10.1200/jco.2013.31.15_suppl.7539
Abstract #
7539
Poster Bd #
20A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Utilization and impact of adjuvant chemotherapy (AC) in surgically resected stages I-III non-small cell lung cancer (NSCLC).
First Author: Christina D. Williams
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2020 ASCO Virtual Scientific Program
Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
First Author: Tina Cascone